Philip Y. Cho philip.cho.wg11@wharton.upenn.edu


University of California at San Diego, La Jolla, CA


B.A., Economics, 2002 B.A., Psychology, 2002


Nigel Cordeiro


nigel.cordeiro.wg11@wharton.upenn.edu Brown University, Providence, RI B.A., Computer Science, 2002


Emilie M. Coueignoux


emilie.coueignoux.wg11@wharton.upenn.edu Wellesley College, Wellesley, MA B.A., Magna Cum Laude, International Relations, 2005


An opportunity in healthcare finance or business development.


Credit Suisse, Seoul, Korea Investment Banking Division, Summer Intern, 2010


Provided M&A advisory coverage to Korean companies and Asian-focused financial sponsors. Performed exten- sive valuation analysis, including DCF and LBO models, comparable analysis and precedent transactions for sell- side engagement for a $200M South Korean auto-parts manufacturer


SK Telecom (SKT), Seoul, Korea Business Development Manager, 2006-2009 Developed business model and performed feasibility analysis of health care related, value-added services. Evaluated new and follow-on investment opportunities through detailed analysis of financial, industry, and competitive trends. Led negotia- tions to drive the global alliance of top-tier mobile operators to jointly develop SKT’s $400M platform, T-PAK.


CHA Health System (CHS), Seoul, Korea Global Strategy Associate, 2003-2005 Performed due diligence and executed global investment and acquisition opportunities in the health care space.


An opportunity to leverage my opera- tional experience to provide strategic leadership in the health care industry.


TriZetto, Denver, CO


Summer Consultant, Summer 2010 Spearheaded economic feasibility and sustainability model for a new business line, state-based Health Insurance Exchanges. TriZetto now uses model as a key sales tool and to demonstrate thought-leadership when approaching state authorities. Presented TriZetto health-exchange offering to PA Governor’s Director of Health Reform


Position2, Palo Alto, CA Client Manager, 2007-2009


Served as single point-of-contact for health care clients representing more than $500K in revenue. Created and executed strategies to increase customer acquisition via the Internet. Managed delivery teams in Bangalore and Mumbai who executed all clients’ marketing campaigns.


McMaster-Carr Supply Co, Los Angeles, CA Supervisor, 2004-2006


Led daily operations for three depart- ments: sales, distribution, and finance. Made strategic changes to improve performance in all three departments, while regularly exceeding quarterly objectives. Directly managed and cross-trained employees (7-15 direct reports), provided daily feedback, and administered annual reviews/salary increases.


PanHealth, Livingston, NJ Analyst, 2002-2004


Ran sales campaigns to launch medication compliance offering for hospitals and pharma companies.


An opportunity at a life science start-up or at a biotech in corporate strategy or business development.


Genzyme, Cambridge, MA Business Development Intern, Oncology, Transplant and Multiple Sclerosis, Summer 2010


Designed and conducted analysis to assess alignment of commercial attractiveness with projected spend on portfolio products. Evaluated and presented potential growth opportu- nity around Genzyme’s first, late-stage Multiple Sclerosis (MS) drug to Senior Director of Business Development and Vice President of Commercial for MS. Developed cash flow scenarios around an in-licensed product; results informed the Business Unit decision to maintain, rather than return or terminate, the license.


L.E.K. Consulting, Boston, MA and Shanghai


Senior Associate Consultant, 2005-2009 Collaborated with head of China’s life science practice to identify potential clients based on assessment of company financials and potential near-term business issues within the Chinese market. Directed team of junior associates to evaluate acquisition opportunities for a top 10 specialty pharmaceutical with a $10B market cap. Designed corporate valuation model to evaluate optimal deal structures for a client’s key pharmaceutical assets within the gastrointestinal, autoimmune and infectious disease spaces, and presented findings to corporate finance team.


10


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40